ZA915962B - Substituted(1h-imidazol-5-yl)alkanoic acids - Google Patents

Substituted(1h-imidazol-5-yl)alkanoic acids

Info

Publication number
ZA915962B
ZA915962B ZA915962A ZA915962A ZA915962B ZA 915962 B ZA915962 B ZA 915962B ZA 915962 A ZA915962 A ZA 915962A ZA 915962 A ZA915962 A ZA 915962A ZA 915962 B ZA915962 B ZA 915962B
Authority
ZA
South Africa
Prior art keywords
imidazol
substituted
alkanoic acids
alkanoic
acids
Prior art date
Application number
ZA915962A
Other languages
English (en)
Inventor
Gerald Robert Girard
Robert Girard Gerald
Judith Hempel
Hempel Judith
David Taylor Hill
Taylor Hill David
James Samanen
Samanen James
Joseph Weinstock
Weinstock Joseph
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of ZA915962B publication Critical patent/ZA915962B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epoxy Resins (AREA)
ZA915962A 1990-07-31 1991-07-30 Substituted(1h-imidazol-5-yl)alkanoic acids ZA915962B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56064390A 1990-07-31 1990-07-31

Publications (1)

Publication Number Publication Date
ZA915962B true ZA915962B (en) 1992-07-29

Family

ID=24238686

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA915962A ZA915962B (en) 1990-07-31 1991-07-30 Substituted(1h-imidazol-5-yl)alkanoic acids

Country Status (11)

Country Link
US (2) US5444080A (es)
EP (1) EP0541705A4 (es)
JP (1) JPH05509106A (es)
AU (1) AU649270B2 (es)
CA (1) CA2087840A1 (es)
IE (1) IE912680A1 (es)
MX (1) MX9100468A (es)
NZ (1) NZ239161A (es)
PT (1) PT98524A (es)
WO (1) WO1992002510A1 (es)
ZA (1) ZA915962B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2689508B1 (fr) * 1992-04-01 1994-06-17 Fournier Ind & Sante Derives de l'imidazole, leur procede de preparation et leur application en therapeutique.
US5728842A (en) * 1992-06-30 1998-03-17 Smithkline Beecham Corporation Substituted imidazolyl-alkylthio-alkanoic acids
GB9213934D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Chemical compounds
AR011125A1 (es) * 1997-02-14 2000-08-02 Smithkline Beecham Corp Procedimiento para preparar eprosartano
AR011126A1 (es) * 1997-02-14 2000-08-02 Smithkline Beecham Corp Procedimiento para preparar eprosartano y compuestos intermediarios.
US20030045561A1 (en) * 2001-02-06 2003-03-06 Smithkline Beecham Corporation Method of treating isolated systolic hypertension
WO1999007365A1 (en) * 1997-08-06 1999-02-18 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
US6630498B2 (en) 1997-08-06 2003-10-07 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
DE60130030T2 (de) * 2000-12-29 2008-04-30 Alteon Inc. Verfahren zur behandlung von glaukom
CN1938021A (zh) * 2004-03-08 2007-03-28 惠氏公司 离子通道调节剂
EP1752450A1 (en) 2005-08-01 2007-02-14 Merck Sante Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PT3004138T (pt) 2013-06-05 2024-06-18 Bausch Health Ireland Ltd Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU60908A1 (es) * 1969-05-21 1970-07-16
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
GR75287B (es) * 1980-07-25 1984-07-13 Ciba Geigy Ag
IE802177L (en) * 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
DE3106150A1 (de) * 1981-02-13 1982-09-16 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verfahren zur herstellung von imidazolessigsaeurederivaten"
JPS58157768A (ja) * 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
PH23251A (en) * 1985-03-18 1989-06-16 Sds Biotech Corp Propionate derivative and nonmedical fungicide containing the same
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
JPS63270666A (ja) * 1987-04-30 1988-11-08 Wakamoto Pharmaceut Co Ltd 新規１−ベンジルイミダゾ−ル誘導体
JPS63303968A (ja) * 1987-06-05 1988-12-12 Sankyo Co Ltd 含窒素複素環誘導体
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
CA2018443A1 (en) * 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids
DK0403159T3 (da) * 1989-06-14 2000-08-14 Smithkline Beecham Corp Imidazolylalkensyrer
CA2027937A1 (en) * 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles
CA2028925A1 (en) * 1989-11-06 1991-05-07 Gerald R. Girard Substituted n-(imidazolyl)alkyl alanine derivatives
CA2032289A1 (en) * 1989-12-29 1991-06-30 Joseph A. Finkelstein Substituted 5-(alkyl) carboxamide imidazoles
NZ238688A (en) * 1990-06-28 1992-05-26 Smithkline Beecham Corp Substituted histidines: pharmaceutical compositions, preparation and uses thereof

Also Published As

Publication number Publication date
NZ239161A (en) 1994-01-26
US5530017A (en) 1996-06-25
JPH05509106A (ja) 1993-12-16
CA2087840A1 (en) 1992-02-01
PT98524A (pt) 1992-06-30
MX9100468A (es) 1992-02-28
EP0541705A1 (en) 1993-05-19
IE912680A1 (en) 1992-02-12
WO1992002510A1 (en) 1992-02-20
EP0541705A4 (en) 1993-11-10
AU649270B2 (en) 1994-05-19
AU8493191A (en) 1992-03-02
US5444080A (en) 1995-08-22

Similar Documents

Publication Publication Date Title
IL94699A0 (en) Imidazolyl-alkenoic acids
IL102813A0 (en) Imidazolyl-alkenoic acids
ZA915962B (en) Substituted(1h-imidazol-5-yl)alkanoic acids
ZA902510B (en) 5-alkylquinolonecarboxylic acids
GB8326030D0 (en) Alkanoic acids
IL87457A0 (en) Substituted 2-phenyl-4-quinoline carboxylic acids
EP0563238A4 (en) Imidazolyl-alkenoic acids
AU561838B2 (en) Alpha alkanoic acids
ZA911398B (en) Carboxylic acid derivatives
ZA913132B (en) Carboxylic acid derivatives
ZA919058B (en) Sulfimidoperoxycarboxylic acids
GB9111974D0 (en) Novel process
HU904504D0 (en) Process for stabilizing carboxylic estherase
CS201289A1 (en) Omega-(2-biphenylyloxy) alkanoic acids
GB8809628D0 (en) Alkanoic acids
GB8809080D0 (en) Alkanoic acids
GB8803517D0 (en) Alkanoic acids
GB8918936D0 (en) Carboxylic acids
GB8709793D0 (en) Alkanoic acids
IE901193L (en) 5-alkylquinolone carboxylic acids
ZA904579B (en) Imidazolyl-alkenoic acids
ZA904580B (en) Imidazolyl-alkenoic acids
IE893493L (en) 3-aminocarboxylic acids
ZW9390A1 (en) Imidazolyl-alkenoic acids
IE900338L (en) Heteroaryl-1-alkyl-pyrrole-2-carboxylic acids